Literature DB >> 28304400

Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.

Renée Mf Ebisch1, Judith van der Horst2, Meyke Hermsen2, L Lucia Rijstenberg2, Judith Em Vedder2, Johan Bulten2, Remko P Bosgraaf1, Viola Mj Verhoef3, Daniëlle Am Heideman3, Peter Jf Snijders3, Chris Jlm Meijer3, Folkert J van Kemenade4, Leon Fag Massuger1, Willem Jg Melchers5, Ruud Lm Bekkers1,6, Albert G Siebers2.   

Abstract

The aim of this study was to evaluate the clinical utility of p16/Ki-67 dual staining, for the identification of CIN in high-risk HPV-positive women from a non-responder screening cohort. P16/Ki-67 dual staining, Pap cytology, and HPV16/18 genotyping were performed on physician-taken liquid-based samples from 495 women who tested high-risk HPV positive on self-sampled material (PROHTECT-3B study). Different triage strategies involving p16/Ki-67 dual staining were evaluated for sensitivity, specificity, and predictive value for ≥CIN2 and ≥CIN3, and compared to Pap cytology with a threshold of atypical cells of undetermined significance. Centrally revised histology or an adjusted endpoint with combined high-risk HPV negative and cytology negative follow-up at 6 months was used as gold standard. Pap cytology (threshold atypical cells of undetermined significance) triage of high-risk HPV-positive samples showed a sensitivity of 93% (95% confidence interval: 85-98) with a specificity of 49% (95% confidence interval: 41-56) for ≥CIN3. Three triage strategies with p16/Ki-67 showed a significantly increased specificity with similar sensitivity. P16/Ki-67 triage of all high-risk HPV-positive samples had a sensitivity of 92% (95% confidence interval: 84-97) and a specificity of 61% (95% confidence interval: 54-69) for ≥CIN3. Applying p16/Ki-67 triage to only high-risk HPV-positive women with low-grade Pap cytology showed a similar sensitivity of 92% (95% confidence interval: 84-97), with a specificity for ≥CIN3 of 64% (95% confidence interval: 56-71). For high-risk HPV-positive women with low-grade and normal Pap cytology, triage with p16/Ki-67 showed a sensitivity of 96% (95% confidence interval: 89-99), and a specificity of 58% (95% confidence interval: 50-65). HPV16/18 genotyping combined with Pap cytology showed a sensitivity and specificity for ≥CIN3 similar to Pap cytology with an atypical cells of undetermined significance threshold. Because the quality of Pap cytology worldwide varies, and differences in sensitivity and specificity are limited between the three selected strategies, p16/Ki-67 triage of all high-risk HPV-positive samples would be the most reliable strategy in triage of high-risk HPV-positive women with an increased specificity and similar sensitivity compared with Pap cytology triage.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28304400     DOI: 10.1038/modpathol.2017.16

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  41 in total

1.  Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy.

Authors:  Maaike G Dijkstra; Dirk van Niekerk; Dorien C Rijkaart; Folkert J van Kemenade; Daniëlle A M Heideman; Peter J F Snijders; Chris J L M Meijer; Johannes Berkhof
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-06-03       Impact factor: 4.254

2.  Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening.

Authors:  Dorien C Rijkaart; Johannes Berkhof; Folkert J van Kemenade; Veerle M H Coupe; Albertus T Hesselink; Lawrence Rozendaal; Danielle A M Heideman; Ren H Verheijen; Saskia Bulk; Wim M Verweij; Peter J F Snijders; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2011-05-05       Impact factor: 7.396

3.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  CA Cancer J Clin       Date:  2012-03-14       Impact factor: 508.702

4.  The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.

Authors:  Renée M F Ebisch; Gabriëlle M de Kuyper-de Ridder; Remko P Bosgraaf; Leon F A G Massuger; Joanna IntHout; Viola M J Verhoef; Daniëlle A M Heideman; Peter J F Snijders; Chris J L M Meijer; Folkert J van Kemenade; Johan Bulten; Albert G Siebers; Ruud L M Bekkers; Willem J G Melchers
Journal:  Int J Cancer       Date:  2016-04-07       Impact factor: 7.396

5.  p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women.

Authors:  Nicolas Wentzensen; Barbara Fetterman; Philip E Castle; Mark Schiffman; Shannon N Wood; Eric Stiemerling; Diane Tokugawa; Clara Bodelon; Nancy Poitras; Thomas Lorey; Walter Kinney
Journal:  J Natl Cancer Inst       Date:  2015-09-15       Impact factor: 13.506

6.  Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology.

Authors:  Elena Allia; Guglielmo Ronco; Anna Coccia; Patrizia Luparia; Luigia Macrì; Corinna Fiorito; Francesca Maletta; Cristina Deambrogio; Sara Tunesi; Laura De Marco; Anna Gillio-Tos; Anna Sapino; Bruno Ghiringhello
Journal:  Cancer Cytopathol       Date:  2014-12-22       Impact factor: 5.284

7.  Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.

Authors:  Nicolas Wentzensen; Lauren Schwartz; Rosemary E Zuna; Katie Smith; Cara Mathews; Michael A Gold; R Andy Allen; Roy Zhang; S Terence Dunn; Joan L Walker; Mark Schiffman
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

8.  The Tahoe Study: bias in the interpretation of Papanicolaou test results when human papillomavirus status is known.

Authors:  Ann T Moriarty; Ritu Nayar; Terry Arnold; Lisa Gearries; Andrew Renshaw; Nicole Thomas; Rhona Souers
Journal:  Arch Pathol Lab Med       Date:  2014-09       Impact factor: 5.534

9.  Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion.

Authors:  Marianne Waldstrøm; Rikke Kølby Christensen; Dorthe Ørnskov
Journal:  Cancer Cytopathol       Date:  2012-09-17       Impact factor: 5.284

10.  Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.

Authors:  Lu-Lu Yu; Wen Chen; Xiao-Qin Lei; Yu Qin; Ze-Ni Wu; Qin-Jing Pan; Xun Zhang; Bai-Feng Chang; Shao-Kai Zhang; Hui-Qin Guo; You-Lin Qiao
Journal:  Oncotarget       Date:  2016-04-19
View more
  11 in total

1.  Dual staining for p16/Ki67 is a more specific test than cytology for triage of HPV-positive women.

Authors:  Carolina Areán-Cuns; Maria Mercado-Gutiérrez; Irene Paniello-Alastruey; Fermín Mallor-Giménez; Alicia Córdoba-Iturriagagoitia; Maria Lozano-Escario; Mercedes Santamaria-Martínez
Journal:  Virchows Arch       Date:  2018-08-09       Impact factor: 4.064

2.  Cervical Cancer Elimination Is Dependent on Women's Self-Tests for Primary Human Papillomavirus Testing Triaged by Methylation Status.

Authors:  Diane M Harper
Journal:  J Clin Oncol       Date:  2022-05-20       Impact factor: 50.717

Review 3.  False Negative Results in Cervical Cancer Screening-Risks, Reasons and Implications for Clinical Practice and Public Health.

Authors:  Anna Macios; Andrzej Nowakowski
Journal:  Diagnostics (Basel)       Date:  2022-06-20

4.  E2/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma.

Authors:  Youn Jin Choi; Ahwon Lee; Tae Jung Kim; Hyun Tak Jin; Yong Bok Seo; Jong Sup Park; Sung Jong Lee
Journal:  J Gynecol Oncol       Date:  2018-02-01       Impact factor: 4.401

5.  Interobserver variability and accuracy of p16/Ki-67 dual immunocytochemical staining on conventional cervical smears.

Authors:  Veronika Kloboves Prevodnik; Tine Jerman; Nataša Nolde; Alenka Repše Fokter; Sandra Jezeršek; Živa Pohar Marinšek; Ulrika Klopčič; Simona Hutter Čelik; Kristina Gornik Kramberger; Maja Primic Žakelj; Urška Ivanuš
Journal:  Diagn Pathol       Date:  2019-05-24       Impact factor: 2.644

6.  Combining HPV DNA load with p16/Ki-67 staining to detect cervical precancerous lesions and predict the progression of CIN1-2 lesions.

Authors:  Yuejie Li; Jie Liu; Li Gong; Xingwang Sun; Wenbo Long
Journal:  Virol J       Date:  2019-10-16       Impact factor: 4.099

7.  FHIT and C-MYC expression in cervical histology and cytology as biomarkers for detecting high-grade intraepithelial neoplasia in human papillomavirus-positive women.

Authors:  Fan Yang; Zifeng Cui; Yuandong Liao; Rui Tian; Weiwen Fan; Zhuang Jin; Zheng Hu; Shuzhong Yao
Journal:  Cancer Biomark       Date:  2020       Impact factor: 4.388

8.  Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.

Authors:  Mark H Stoler; Ed Baker; Sean Boyle; Shagufta Aslam; Ruediger Ridder; Warner K Huh; Thomas C Wright
Journal:  Int J Cancer       Date:  2019-10-06       Impact factor: 7.396

9.  Implementation of p16/Ki67 dual stain cytology in a Danish routine screening laboratory: Importance of adequate training and experience.

Authors:  Anne Hammer; Line W Gustafson; Pia N Christensen; Rikke Brøndum; Berit Andersen; Rikke H Andersen; Mette Tranberg
Journal:  Cancer Med       Date:  2020-09-07       Impact factor: 4.452

10.  The Association of Molecular Biomarkers in the Diagnosis of Cervical Pre-Cancer and Cancer and Risk Factors in Senegalese.

Authors:  Dominique Diouf; Gora Diop; Cheikh Fall; Souleymane Sarr; Cheikh Ahmadou Tidian Diarra; Aminata Issa Ngom; Sidy Ka; Seynabou Lo; Oumar Faye; Ahmadou Dem
Journal:  Asian Pac J Cancer Prev       Date:  2020-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.